Axxion S.A.’s AstraZeneca AZN Stock Holding History

Axxion S.A.’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	+9,607	New	+$1.81M	0.1%	137

Other funds holding AZN

EPGL

Evelyn Partners Group Ltd London $46.9B AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $148B AUM

Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Axxion S.A.'s AZN Position: Q2 2026 in Review

Axxion S.A. opened a new position in AstraZeneca (AZN) in Q2 2026: 9,607 shares worth $1.35M. The stake represents 0.1% of the portfolio and ranks #137 among its holdings.

1,383 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Axxion S.A. held 9,607 shares of AstraZeneca worth $1.35M as of Q2 2026.
AstraZeneca was a new Axxion S.A. position in Q2 2026.
AstraZeneca made up 0.1% of Axxion S.A.'s portfolio in Q2 2026, its #137 holding.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Axxion S.A.'s 13F filing for Q2 2026, filed 14 Aug 2026.